News Column

Data on Stem Cells Discussed by Researchers at Zhejiang University (Superiority of preemptive donor lymphocyte infusion based on minimal residual...

July 23, 2014



Data on Stem Cells Discussed by Researchers at Zhejiang University (Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation)

By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Stem Cell Research. According to news reporting from Hangzhou, People's Republic of China, by NewsRx journalists, research stated, "Donor lymphocyte infusion (DLI) was used as salvage therapy in leukemia relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT), but existing results on DLI administration to acute leukemia patients were disappointing. Although increasing minimal residual disease (MRD) after HSCT had been proven to be highly indicative of posttransplant relapse, preemptive DLI (pDLI) based on MRD has not been well evaluated."

The news correspondents obtained a quote from the research from Zhejiang University, "We retrospectively analyzed 70 acute leukemia patients after allo-HSCT in our center between January 2005 and December 2010. Sixteen patients received pDLIs based on increasing MRD results (pDLI group), and 11 relapsed patients received therapeutic DLIs with or without chemotherapy (tDLI group). Donor lymphocytes were collected from the original donors without stimulation and infused without further manipulation. The median mononuclear cell doses and CD3+ cell doses were 1.49x108 and 5.51x107/kg. Forty-three patients who did not receive pDLI therapy after detecting increasing MRD (no pDLI group) were also included as a comparison. The response rate was 100% in the pDLI group, whereas it was 63.6% in the tDLI group (p=0.019). Survival outcomes were superior in the pDLI group compared with the tDLI group (2=14.624, p=0.000); estimated overall survival (OS) at 1 year was 93.8% with pDLI and 27.3% with tDLI. The incidence of overall acute graft-versus-host disease (aGVHD) and Grade III to IV aGVHD was higher in the pDLI group but with no significance. Patients in the no pDLI group showed an inferior prognosis with 1-year OS at 65.1% (95% confidence interval, 50.8%-79.4%)."

According to the news reporters, the research concluded: "Our results demonstrated the efficacy and safety of pDLI and suggested that pDLI based on MRD monitoring was superior in acute leukemia patients with potential progression compared with salvage DLI administrated in overt relapse."

For more information on this research see: Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Transfusion, 2014;54(6):1493-1500. Transfusion can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Transfusion - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1537-2995)

Our news journalists report that additional information may be obtained by contacting Y.M. Tan, Zhejiang University, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Center, Hangzhou 310003, Zhejiang, People's Republic of China. Additional authors for this research include K.L. Du, Y. Luo, J.M. Shi, L. Cao, Y.L. Zheng, G.F. Zheng, Y.M. Zhao, X.J. Ye, Z. Cai and H. Huang (see also Stem Cell Research).

Keywords for this news article include: Asia, Surgery, Hangzhou, Oncology, Hematology, Immunology, Blood Cells, Lymphocytes, Acute Leukemia, Bone Marrow Cells, Residual Neoplasms, Stem Cell Research, Cell Transplantation, Mononuclear Leukocytes, Hematopoietic Stem Cells, Hemic and Immune Systems, People's Republic of China

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters